Expression of CXCR3 on Mononuclear Cells and CXCR3 Ligands in Patients With Metastatic Renal Cell Carcinoma in Response to Systemic IL-2 Therapy
- 1 May 2007
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Immunotherapy
- Vol. 30 (4), 417-424
- https://doi.org/10.1097/cji.0b013e31802e089a
Abstract
Summary: Chemokines play an important role in regulating tumor-mediated immunity, angiogenesis, and tumor cell metas- tasis. The chemokine receptor, CXCR3, is expressed in various human tumors, including renal cell carcinoma (RCC). CXCR3 is also associated with antiangiogenic effects in multiple tumors, and we hypothesized that interleukin-2 (IL-2) treatment of patients with metastatic clear cell RCC could augment CXCR3 levels on circulating mononuclear cells and correlate to out- come. The kinetics of CXCR3 expression on circulating mono- nuclear cells and its ligands (CXCL9, CXCL10, and CXCL11) in plasma were evaluated in 20 patients with metastatic clear cell RCC during cycles 1 and 2 of high dose IL-2 therapy. Subpopulations of peripheral blood mononuclear cells (PBMCs) were studied by dual color flow cytometry. Angiogenic ligands were measured and an ''angiogenic ratio'' was calculated prehigh and posthigh dose IL-2. CXCR3 expression on PBMC at baseline was similar in patients with metastatic RCC and normal controls. PBMC CXCR3 expression increased during treatment, and peaked during cycle 2. Plasma from RCC patients displayed similar baseline levels of CXCR3 ligands to normal controls. However, the angiogenic ratio was significantly increased in patients with metastatic RCC at baseline. Plasma levels of CXCR3 ligands increased during treatment, resulting in a reversal in the angiogenic ratio to favor angiostatic chemokines. The CXCR3/CXCR3 ligand biologic axis and angiogenic ratio may be important biomarkers in clear cell RCC patients who are undergoing high dose IL-2 therapy.Keywords
This publication has 36 references indexed in Scilit:
- Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2005
- Cancer Statistics, 2005CA: A Cancer Journal for Clinicians, 2005
- Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trialBritish Journal of Cancer, 2003
- Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal CancerJournal of Clinical Oncology, 2003
- A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal CancerThe New England Journal of Medicine, 2003
- RENAL CELL CARCINOMA: MANAGEMENT OF ADVANCED DISEASEJournal of Urology, 1999
- Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell CarcinomaThe New England Journal of Medicine, 1998
- Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.Journal of Clinical Oncology, 1995
- Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.Proceedings of the National Academy of Sciences of the United States of America, 1994
- Mutations of the VHL tumour suppressor gene in renal carcinomaNature Genetics, 1994